• PDF / 169,404 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 104 Downloads / 169 Views

DOWNLOAD

REPORT

---

1 S

QT interval prolongation and status epilepticus: 2 case reports A retrospective cohort analysis of patients who had been enrolled on multidrug-resistant tuberculosis (MDR-TB) treatment at a hospital in Papua New Guinea, from 01 July 2015 to 31 December 2017 described two patients [ages and sexes not stated], of whom, one patient developed status epilepticus during treatment with isoniazid; while the another patient exhibited QT-interval prolongation during treatment with bedaquiline for MDR-TB. Both the patients started receiving bedaquiline for MDR-TB. One of the these patients had also been receiving isoniazid. The patient, who had been receiving bedaquiline and isoniazid, subsequently developed isoniazid-related grade 4 status epilepticus; while the another patient exhibited exhibited grade 3 QT-interval prolongation, which was determined to be related to bedaquiline [durations of treatments to reactions onsets not stated]. Both the patients required hospitalization due to the adverse-effects. Additionally, the patient, who exhibited QT-prolongation, discontinued bedaquiline [outcomes not stated]. Taune M, et al. Successful implementation of bedaquiline for multidrug-resistant tb treatment in remote Papua New Guinea. Public Health Action 9 (Suppl. 1): S73-S79, 21 803514586 Sep 2019. Available from: URL: http://doi.org/10.5588/pha.18.0071

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830